Questions about whether acetaminophen use during pregnancy can lead children to develop neurological problems have sparked scientific inquiry and litigation. Lawsuits are continuing, but a new National Institutes of Health-sponsored study has results that show no causal link between acetaminophen and neurodevelopmental disorders.
Long Covid continues to afflict patients and mystify clinicians. The National Institutes of Health is trying to identify potential treatments and it is launching a series of clinical trials that will assess a wide range of therapeutic interventions.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Marburg virus has no FDA-approved vaccines or therapies, but a vaccine candidate from the National Institutes of Health now has encouraging results from a U.S. clinical trial. Next steps include tests in more countries including Ghana, where a Marburg outbreak was declared last summer.
Johnson & Johnson reported results from a mid-stage study in southern Africa showing just 25% efficacy for its HIV vaccine. J&J developed the HIV vaccine with the same technology used in its successful Ebola and Covid-19 vaccines.
Antibody therapies from Brii Biosciences and Vir Biotechnology failed to show sufficient efficacy to advance to the next stage of an NIH-sponsored Covid-19 clinical trial. Apellis Pharmaceuticals and Durect also stopped work on experimental Covid treatments.
The agency's Covid-19 Treatment Guidelines Panel stated there was insufficient evidence for or against the treatment and pointed out that in certain groups, such as intubated patients, no benefit in seven-day overall survival was observed.
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
The New York Times reported that the FDA was prepared to issue an emergency use authorization for the treatment last week, but NIH Director Francis Collins and NIAID Director Anthony Fauci intervened, arguing that data were too weak.
The NIAID create the Covid-19 Prevention Trials Network by combining four existing ones, primarily focused on HIV and AIDS, which will continue that work in addition to their new focus on Covid-19.
A preprint retrospective analysis among 368 patients hospitalized with Covid-19 in the VA system found no benefit and a higher degree of death from hydroxychloroquine. A panel of experts also recommended against using the drug with azithromycin outside of trials due to potential toxicity.
Our weekly cartoon focuses on the National Institutes of Health.
We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.
It's likely that many drugs Americans take for granted wouldn't exist today if not for the NIH-funded basic research that enabled their discovery and development. Fortunately, generous funding for the NIH has long enjoyed bipartisan support in Congress.
The partnership will have a particular focus on therapies to treat sickle cell disease and HIV, with each party committing $100 million to the effort.
The partnership builds on an existing relationship between All of Us and Color, which was chosen as one of three genome centers that are responsible for actual genotyping of patient samples.
Science magazine reported that the move put the brakes on a preclinical HIV study and follows the cancellation of a contract between the FDA and a California-based company that supplies fetal tissue for medical research.
The company is hoping to boost the adoption of AI in medical imaging with new software development kits and deals with Ohio State University and the NIH.